• Home
  • About Journal
    Journal Introduction
    Editorial Board
    Youth Editorial Board
    Cooperating Institutions
    Editorial Department
  • Submission Guidelines
  • Policies & Statements
    Ethical Guidelines for Publication
    Academic Misconduct Statement
    Open Access (OA) Statement
    AIGC Use Statement
  • Journal Subscription
  • Download Center
  • 中文版
Cite this article:
HU Yajie,HAN Tian,LU Tao,HU Qinghua.Research progress on tumor-associated macrophages involved in the mechanism of bevacizumab resistance[J].Journal Of Pharmaceutical Research,2022,41(5):322-325[Click to copy]
【Print this page】      【Download PDF Full Text】   【View/Add Comment】  【Download reader】  【 Close 】
←Previous|Next→ Archive    Advanced Search
This article has been viewed: 2436times   Download 2254次 QR Code for this article
Scan with your phone!
肿瘤相关巨噬细胞参与贝伐单抗耐药机制的研究进展
胡亚杰1,2,韩天2,陆滔2,胡庆华1
Font:Larger+|Default|Smaller-
(1.中国药科大学药学院,江苏 南京 211198;2.上海药明康德新药开发有限公司,上海 200131)
摘要:
贝伐单抗是获得美国食品药品监督管理局(FDA)批准上市的抗肿瘤血管生成药物,其耐药问题的出现对临床治疗产生了重大影响。因此,阐明其耐药机制、延缓、克服耐药可提高贝伐单抗的临床效果,有效延长肿瘤患者的生存期。在贝伐单抗治疗过程中,巨噬细胞被招募到肿瘤组织或微环境中,并进一步转变为肿瘤相关巨噬细胞(tumor-associated macrophages,TAM),从而驱动肿瘤的发生发展。本文就肿瘤相关巨噬细胞参与贝伐单抗耐药机制的研究现状予以综述,旨在系统性地阐明肿瘤相关巨噬细胞在肿瘤增殖和转移中的作用,为缓解或消除贝伐单抗的耐药提供理论支持。
关键词:  贝伐单抗  肿瘤相关巨噬细胞  耐药机制  肿瘤细胞
DOI:10.13506/j.cnki.jpr.2022.05.010
基金项目:
Publication Date:May 25, 2022
Research progress on tumor-associated macrophages involved in the mechanism of bevacizumab resistance
HU Yajie1,2,HAN Tian2,LU Tao2,HU Qinghua1
(1.School of Pharmacy, China Pharmaceutical University, Nanjing 211198, China; 2.WuXi AppTec(Shanghai) Co.,Ltd., Shanghai 200131, China)
Abstract:
Bevacizumab is an anti-tumor angiogenesis drug approved by the FDA. With the deepening of treatment, the emergence of its drug resistance has a significant impact on clinical treatment. Therefore, clarifying the mechanism of drug resistance, delaying and overcoming drug resistance can improve the clinical efficacy of bevacizumab and effectively prolong the survival period of cancer patients. During the treatment of bevacizumab, macrophages are recruited into tumor tissues and further transformed into tumor-associated macrophages promotes the occurrence and development of tumors. This article reviewed the current research status of tumor-associated macrophages involved in bevacizumab resistance, aiming to systematically clarify the role of tumor-associated macrophages in tumor proliferation, invasion and metastasis, and provided theoretical support for the use of effective means to alleviate or eliminate bevacizumab resistance.
Key words:  Bevacizumab  Tumor-associated macrophages  Resistance mechanisms  Tumor cell
Today's Visits:509    Total Visits:2383239
Website copyright:Editorial Board of Journal of Pharmaceutical Research     鲁ICP备17018036号-3     鲁公网安备 37010202001351号
Sponsored by:Shandong Institute for Food and Drug Control Shandong Pharmaceutical Association Address:No.2749 Xinluo Street,High-Tech Zone,Jinan,P.R.China Postcode:250101
Telephone Number:0531-81216586 Email :yaoxueyanjiu@163.com;yaoxueyanjiu@126.com
Technical Support:Beijing Qinyun Technology Co., Ltd.